Idt Australia Limited · ASX:IDT
Idt Australia — Shareholder Meeting (November 2022)
10 slides from Idt Australia's shareholder meeting presentation, Nov 28, 2022
Slide 1: IDT Australia Limited 2022 Full Year Results and Investor Update
For personal use only IDT AUSTRALIA LIMITED 2022 FULL YEAR RESULTS AND INVESTOR UPDATE November 2022
Slide 2: Australia Pandemic Opportunities: Sterile Manufacturing
Australia Pandemic Opportunities Sterile Manufacturing For personal use only ▪ Federal Government Contract completed in Q2 ▪ First Sterile (Aseptic) Manufacturing License Extension from the TGA Q2 ▪ Site is manufacturing ready with capacity of up to 100M vaccine doses (assumes 10-16 doses per vial,
Slide 3: Investing in Growth: Capability and Capacity Investment
Investing in Growth Capability and Capacity Investment For personal use only ▪ Sterile manufacturing facility enhancement and completion of TGA CAPA’s throughout 2022 ▪ Further investment in encapsulation machine with capacity of 200,000 units per day ▪ IDT continues to offer advanced and complex ph
Slide 4: Key Financial Highlights
Key Financial Highlights For personal use only ▪ First Half of FY22 produced revenue of $8.56M and EBITDA of $1.98M. Full Year Results FY22 vs FY21 ($'000) ▪ FY22 Revenue decrease of 40% to $12.3 million over Actual FY21 FY 22 FY 21 ▪ FY22 EBITDA decreased by $3.5million to $376k over Revenue $12,13
Slide 5: Sovereign Manufacturing
Sovereign Manufacturing For personal use only ▪ IDT completed several unsuccessful bids within government initiatives, including: ▪ Modern Manufacturing Initiative (MMI) ▪ Translation & Collaboration Streams ▪ Medical Research Future Fund (MRFF) ▪ IDT continues to explore opportunities to develop so
Slide 6: Building Capacity & Capability
Building Capacity & Capability For personal use only ▪ Build for Growth strategy ▪ Increased Focus on Business and Pipeline Development ▪ IDT’s has a proven record of Product Development Delivery ▪ 12,000sqm of R&D and Manufacturing Facilities in API, Capsule, Tablet, Oral Liquid & Injectables. Broa
Slide 7: Advancing Technology RNA Opportunity
Advancing Technology RNA Opportunity For personal use only ▪ Record Investment in mRNA platforms disrupting the Biotechnology Sector ▪ Moderna2 Investment at Federal & State levels ▪ Vic mRNA Invests $50M into BioNTech3 ▪ NSW Government >$200M Macquarie Park4 ▪ Unprecedented spend in research locall
Slide 8: Medicinal Cannabis & Psychedelics
Medicinal Cannabis & Psychedelics For personal use only ▪ Evolving medicinal cannabis ecosystem ▪ Medical grade supplies available for import and now readily available grown locally. IDT GMP standards are amongst the highest within the industry and IDT is well positioned for the TGA regulatory refor
Slide 9: The Year Ahead
The Year Ahead For personal use only ▪ Established Assets and Programs generate Opportunities for greater volume, absorb cost of Quality and return to profitability ▪ IDT continues to explore opportunities to develop sovereign manufacturing capabilities and in particular address critical drug shorta
Slide 10: Disclaimer
For personal use only DISCLAIMER This presentation contains forward looking statements which involve known and unknown risks. By their nature, forward looking statements involve risk and uncertainty because they relate to future events and circumstances and there are many factors which could cause a